Taha Bat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Taha Bat has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Weina Chen
Department of Pathology University of Texas Southwestern Medical Center Dallas Texas USA
5 shared publications Ibrahim Ibrahim
Division of Hematology‐Oncology University of Texas Southwestern Medical Center Dallas Texas USA
4 shared publications- Carmelo Gurnari
Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy
3 shared publications - Jaroslaw P. Maciejewski
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
3 shared publications Mutlu Mete
Department of Computer Science and Information Systems Texas A&M University‐Commerce Commerce Texas USA
3 shared publicationsBhavisha Patel
National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda Maryland USA
2 shared publications
Latest Publications
- Open Access
- 25 August 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (4) , 100163
Predicting secondary myeloid neoplasms in acquired aplastic anemia using machine learning models
- 25 August 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (4) , 100163
Open AccessPredicting secondary myeloid neoplasms in acquired aplastic anemia using machine learning models
- 18 December 2024
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 47 (2) , 357-361
Absolute Immature Platelet Count: An Accessible Biomarker to Distinguish Aplastic Anemia and Immune Thrombocytopenia
- 18 December 2024
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 47 (2) , 357-361
Absolute Immature Platelet Count: An Accessible Biomarker to Distinguish Aplastic Anemia and Immune Thrombocytopenia
- Open Access
- 12 June 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (12) , 3058-3062
Thrombocytosis and megakaryocyte changes associated with PRCA
Joelle Abdallah, Robert George Williams, Hussein Awada, Ganesh Raman, Yusuf M Ozcan, Mark David Orland, Mutlu Mete, Weina Chen, Carmelo Gurnari, Jaroslaw P Joelle Abdallah, Robert George Williams, Hussein Awada, Ganesh Raman, Yusuf M Ozcan, Mark David Orland, Mutlu Mete, Weina Chen, Carmelo Gurnari, Jaroslaw P
- 12 June 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (12) , 3058-3062
Open AccessThrombocytosis and megakaryocyte changes associated with PRCA
Joelle Abdallah, Robert George Williams, Hussein Awada, Ganesh Raman, Yusuf M Ozcan, Mark David Orland, Mutlu Mete, Weina Chen, Carmelo Gurnari, Jaroslaw P Joelle Abdallah, Robert George Williams, Hussein Awada, Ganesh Raman, Yusuf M Ozcan, Mark David Orland, Mutlu Mete, Weina Chen, Carmelo Gurnari, Jaroslaw P
- 12 March 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 2121-2124
Ahemolytic PNH (white cell PNH): Clinical features and implications of a distinct phenotype of paroxysmal nocturnal haemoglobinuria
- 12 March 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 2121-2124
Ahemolytic PNH (white cell PNH): Clinical features and implications of a distinct phenotype of paroxysmal nocturnal haemoglobinuria
- Open Access
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 15
Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder which is caused by mutations in phosphatidylinositol glycan class A leading to hemolysis of red blood cells via complement inhibition. The first treatment for PNH, eculizumab, was FDA approved in 2007. Since then, many new treatment options for PNH have arisen. This critical review will examine all medications available for PNH on the US market, highlight several major medications in development, and discuss the risks and treatment considerations associated with each option. It is not intended to address PNH clonal dynamics, disease presentation, or discussions on when to initiate treatment.
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 15
Open AccessCurrent landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder which is caused by mutations in phosphatidylinositol glycan class A leading to hemolysis of red blood cells via complement inhibition. The first treatment for PNH, eculizumab, was FDA approved in 2007. Since then, many new treatment options for PNH have arisen. This critical review will examine all medications available for PNH on the US market, highlight several major medications in development, and discuss the risks and treatment considerations associated with each option. It is not intended to address PNH clonal dynamics, disease presentation, or discussions on when to initiate treatment.
- Open Access
- 7 March 2023
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 23 (1) , 1-6
Machine learning prediction for COVID-19 disease severity at hospital admission
Importance: Early prognostication of patients hospitalized with COVID-19 who may require mechanical ventilation and have worse outcomes within 30 days of admission is useful for delivering appropriate clinical care and optimizing resource allocation. Objective: To develop machine learning models to predict COVID-19 severity at the time of the hospital admission based on a single institution data. Design, setting, and participants: We established a retrospective cohort of patients with COVID-19 from University of Texas Southwestern Medical Center from May 2020 to March 2022. Easily accessible objective markers including basic laboratory variables and initial respiratory status were assessed using Random Forest’s feature importance score to create a predictive risk score. Twenty-five significant variables were identified to be used in classification models. The best predictive models were selected with repeated tenfold cross-validation methods. Main outcomes and measures: Among patients with COVID-19 admitted to the hospital, severity was defined by 30-day mortality (30DM) rates and need for mechanical ventilation. Results: This was a large, single institution COVID-19 cohort including total of 1795 patients. The average age was 59.7 years old with diverse heterogeneity. 236 (13%) required mechanical ventilation and 156 patients (8.6%) died within 30 days of hospitalization. Predictive accuracy of each predictive model was validated with the 10-CV method. Random Forest classifier for 30DM model had 192 sub-trees, and obtained 0.72 sensitivity and 0.78 specificity, and 0.82 AUC. The model used to predict MV has 64 sub-trees and returned obtained 0.75 sensitivity and 0.75 specificity, and 0.81 AUC. Our scoring tool can be accessed at https://faculty.tamuc.edu/mmete/covid-risk.html. Conclusions and relevance: In this study, we developed a risk score based on objective variables of COVID-19 patients within six hours of admission to the hospital, therefore helping predict a patient's risk of developing critical illness secondary to COVID-19.
- 7 March 2023
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 23 (1) , 1-6
Open AccessMachine learning prediction for COVID-19 disease severity at hospital admission
Importance: Early prognostication of patients hospitalized with COVID-19 who may require mechanical ventilation and have worse outcomes within 30 days of admission is useful for delivering appropriate clinical care and optimizing resource allocation. Objective: To develop machine learning models to predict COVID-19 severity at the time of the hospital admission based on a single institution data. Design, setting, and participants: We established a retrospective cohort of patients with COVID-19 from University of Texas Southwestern Medical Center from May 2020 to March 2022. Easily accessible objective markers including basic laboratory variables and initial respiratory status were assessed using Random Forest’s feature importance score to create a predictive risk score. Twenty-five significant variables were identified to be used in classification models. The best predictive models were selected with repeated tenfold cross-validation methods. Main outcomes and measures: Among patients with COVID-19 admitted to the hospital, severity was defined by 30-day mortality (30DM) rates and need for mechanical ventilation. Results: This was a large, single institution COVID-19 cohort including total of 1795 patients. The average age was 59.7 years old with diverse heterogeneity. 236 (13%) required mechanical ventilation and 156 patients (8.6%) died within 30 days of hospitalization. Predictive accuracy of each predictive model was validated with the 10-CV method. Random Forest classifier for 30DM model had 192 sub-trees, and obtained 0.72 sensitivity and 0.78 specificity, and 0.82 AUC. The model used to predict MV has 64 sub-trees and returned obtained 0.75 sensitivity and 0.75 specificity, and 0.81 AUC. Our scoring tool can be accessed at https://faculty.tamuc.edu/mmete/covid-risk.html. Conclusions and relevance: In this study, we developed a risk score based on objective variables of COVID-19 patients within six hours of admission to the hospital, therefore helping predict a patient's risk of developing critical illness secondary to COVID-19.
- Open Access
- 22 December 2022
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (1) , 8
Hepatitis C Infection Associated with Acquired Pure Red Cell Aplasia
Acquired pure red cell aplasia is a rare bone marrow failure disorder characterized by many underlying etiologies. The hallmark bone marrow feature is the near absence of erythroid precursors that otherwise exhibit normal cellularity, which has been attributed to both immune- and cellular-mediated mechanisms. Besides being merely speculative and considering the rarity of the disorder, the description of acquired pure red cell aplasia clinical associations represents a unique occasion to improve our current clinical knowledge of the disease, reveal clues on its pathogenesis, and guide therapeutic decisions. The varied clinical scenarios and common acquired pure red cell aplasia associated conditions (i.e., thymoma, T cell/NK-cell large granular lymphocyte leukemia, B cell dyscrasia) suggest a heterogeneity of pathogenic routes. Viral etiologies must always be considered and worked up in the initial assessment of newly diagnosed acquired pure red cell aplasia patients. In this report, we present two cases of hepatitis-C-related acquired pure red cell aplasia and successful use of anti-viral strategies in the achievement of a complete response.
- 22 December 2022
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (1) , 8
Open AccessHepatitis C Infection Associated with Acquired Pure Red Cell Aplasia
Acquired pure red cell aplasia is a rare bone marrow failure disorder characterized by many underlying etiologies. The hallmark bone marrow feature is the near absence of erythroid precursors that otherwise exhibit normal cellularity, which has been attributed to both immune- and cellular-mediated mechanisms. Besides being merely speculative and considering the rarity of the disorder, the description of acquired pure red cell aplasia clinical associations represents a unique occasion to improve our current clinical knowledge of the disease, reveal clues on its pathogenesis, and guide therapeutic decisions. The varied clinical scenarios and common acquired pure red cell aplasia associated conditions (i.e., thymoma, T cell/NK-cell large granular lymphocyte leukemia, B cell dyscrasia) suggest a heterogeneity of pathogenic routes. Viral etiologies must always be considered and worked up in the initial assessment of newly diagnosed acquired pure red cell aplasia patients. In this report, we present two cases of hepatitis-C-related acquired pure red cell aplasia and successful use of anti-viral strategies in the achievement of a complete response.
- Open Access
- 1 July 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (13) , 3840-3843
SARS-CoV-2 infection associated with aplastic anemia and pure red cell aplasia
- 1 July 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (13) , 3840-3843
Open AccessSARS-CoV-2 infection associated with aplastic anemia and pure red cell aplasia
- Open Access
“Ideal” parathyroid hormone in erythropoietin‐stimulating agents‐resistant anemia
Erythropoietin-stimulating agents (ESAs) have revolutionized anemia treatment in end-stage renal disease (ESRD), but ESA resistance is increasingly identified. Secondary hyperparathyroidism (SHP) is one cause of ESA resistance. We describe a patient with ESA-resistant, transfusion-dependent anemia and mild SHP with remodeling and reticulin fibrosis on bone marrow biopsy, all of which resolved with stricter SHP management. We identified 64 patients with anemia, ESRD, and bone marrow biopsy. The parathyroid hormone (PTH) range for bony remodeling was 183–16,161.9 pg/ml versus 90.8–3283 pg/ml. The PTH range for fibrotic changes was 183–2487 pg/ml versus 90.8–16,161.9 pg/ml. We found no clear PTH range predictive for bone marrow changes.
Open Access“Ideal” parathyroid hormone in erythropoietin‐stimulating agents‐resistant anemia
Erythropoietin-stimulating agents (ESAs) have revolutionized anemia treatment in end-stage renal disease (ESRD), but ESA resistance is increasingly identified. Secondary hyperparathyroidism (SHP) is one cause of ESA resistance. We describe a patient with ESA-resistant, transfusion-dependent anemia and mild SHP with remodeling and reticulin fibrosis on bone marrow biopsy, all of which resolved with stricter SHP management. We identified 64 patients with anemia, ESRD, and bone marrow biopsy. The parathyroid hormone (PTH) range for bony remodeling was 183–16,161.9 pg/ml versus 90.8–3283 pg/ml. The PTH range for fibrotic changes was 183–2487 pg/ml versus 90.8–16,161.9 pg/ml. We found no clear PTH range predictive for bone marrow changes.
- Open Access
- 11 July 2021
- Published by Wiley in British Journal of Haematology
- Vol. 194 (3) , 530-536
Immature platelets as a biomarker for disease severity and mortality in COVID‐19 patients
Summary: COVID‐19, caused by SARS‐CoV‐2, is a contagious life‐threatening viral disease that has killed more than three million people worldwide to date. Attempts have been made to identify biomarker(s) to stratify disease severity and improve treatment and resource allocation. Patients with SARS‐COV‐2 infection manifest with a higher inflammatory response and platelet hyperreactivity; this raises the question of the role of thrombopoiesis in COVID‐19 infection. Immature platelet fraction (IPF, %) and immature platelet counts (IPC, ×109/l) can be used to assess thrombopoiesis. This study investigates whether the level of thrombopoiesis correlates with COVID‐19 severity. A large cohort of 678 well‐characterized COVID‐19 patients was analyzed, including 658 (97%) hospitalized and 139 (21%) admitted to the intensive care unit (ICU). Elevated percentage IPF at presentation was predictive of length of hospitalization (P < 0·01) and ICU admission (P < 0·05). Additionally, percentage IPF at the peak was significantly higher among ICU patients than non‐ICU patients (6·9 ± 5·1 vs 5·3 ± 8·4, P < 0·01) and among deceased patients than recovered patients (7·9 ± 6·3 vs 5·4 ± 7·8, P < 0·01). Furthermore, IPC at the peak was significantly higher among ICU patients than non‐ICU patients (18·5 ± 16·2 vs. 13·2 ± 8·3, P < 0·05) and among patients on a ventilator than those not (22·1 ± 20·1 vs.13·4 ± 8·4, P < 0·05). Our study demonstrated that elevated initial and peak values of percentage IPF and IPC might serve as prognostic biomarkers for COVID‐19 progression to severe conditions.
- 11 July 2021
- Published by Wiley in British Journal of Haematology
- Vol. 194 (3) , 530-536
Open AccessImmature platelets as a biomarker for disease severity and mortality in COVID‐19 patients
Summary: COVID‐19, caused by SARS‐CoV‐2, is a contagious life‐threatening viral disease that has killed more than three million people worldwide to date. Attempts have been made to identify biomarker(s) to stratify disease severity and improve treatment and resource allocation. Patients with SARS‐COV‐2 infection manifest with a higher inflammatory response and platelet hyperreactivity; this raises the question of the role of thrombopoiesis in COVID‐19 infection. Immature platelet fraction (IPF, %) and immature platelet counts (IPC, ×109/l) can be used to assess thrombopoiesis. This study investigates whether the level of thrombopoiesis correlates with COVID‐19 severity. A large cohort of 678 well‐characterized COVID‐19 patients was analyzed, including 658 (97%) hospitalized and 139 (21%) admitted to the intensive care unit (ICU). Elevated percentage IPF at presentation was predictive of length of hospitalization (P < 0·01) and ICU admission (P < 0·05). Additionally, percentage IPF at the peak was significantly higher among ICU patients than non‐ICU patients (6·9 ± 5·1 vs 5·3 ± 8·4, P < 0·01) and among deceased patients than recovered patients (7·9 ± 6·3 vs 5·4 ± 7·8, P < 0·01). Furthermore, IPC at the peak was significantly higher among ICU patients than non‐ICU patients (18·5 ± 16·2 vs. 13·2 ± 8·3, P < 0·05) and among patients on a ventilator than those not (22·1 ± 20·1 vs.13·4 ± 8·4, P < 0·05). Our study demonstrated that elevated initial and peak values of percentage IPF and IPC might serve as prognostic biomarkers for COVID‐19 progression to severe conditions.